Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial
Tate et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.00054-25
https://c19early.org/tate.html